|
Market Closed -
Other stock markets
|
After hours 08:00:00 pm | |||
| 33.64 USD | -1.87% |
|
33.31 | -0.98% |
| Jul. 10 | Sector Update: Health Care Stocks Rise Late Afternoon | MT |
| Jul. 10 | Sector Update: Health Care Stocks Rise Thursday Afternoon | MT |
Business description: Moderna, Inc.
- revenue from product sales (97.4%);
- grant revenue (1.4%);
- revenue from collaboration agreements (1.2%).
At the end of 2023, the group possessed a portfolio of 41 products in clinical development, of which 6 in phase III, 12 in phase II and 18 in phase I, and 5 products in preclinical development.
Net sales are distributed geographically as follows: the United States (27.7%), Europe (19.8%) and other (52.5%).
Number of employees: 5,800
Sales by Activity: Moderna, Inc.
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
Biotechnology | 803M | 18.47B | 19.26B | 6.85B | 3.24B |
Geographical breakdown of sales: Moderna, Inc.
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
United States | 765M | 6.18B | 5.15B | 1.9B | 1.78B |
Rest of World | 38.87M | 5.45B | 7.3B | 3.6B | 853M |
Europe | - | 6.85B | 6.82B | 1.36B | 598M |
Executive Committee: Moderna, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Stéphane Bancel
CEO | Chief Executive Officer | 52 | 2011-02-28 |
James Mock
DFI | Director of Finance/CFO | 48 | 2022-09-05 |
Stephen Hoge
PSD | President | 49 | 2024-10-31 |
Jerh Collins
CTO | Chief Tech/Sci/R&D Officer | - | 2022-12-31 |
| Chief Tech/Sci/R&D Officer | 53 | 2024-11-06 |
Composition of the Board of Directors: Moderna, Inc.
| Director | Title | Age | Since |
|---|---|---|---|
Paul Sagan
BRD | Director/Board Member | 66 | 2018-05-31 |
Noubar Afeyan
CHM | Chairman | 62 | 2012-01-31 |
Stéphane Bancel
BRD | Director/Board Member | 52 | 2011-02-28 |
Francois Nader
BRD | Director/Board Member | 68 | 2019-12-10 |
Sandra Horning
BRD | Director/Board Member | 76 | 2020-02-29 |
| Director/Board Member | 76 | 2020-06-30 | |
Elizabeth Nabel
BRD | Director/Board Member | 73 | 2015-11-30 |
David Rubenstein
BRD | Director/Board Member | 75 | 2024-08-04 |
Shah Hussain
BRD | Director/Board Member | 60 | 2024-10-01 |
Holdings: Moderna, Inc.
| Name | Equities | % | Valuation |
|---|---|---|---|
METAGENOMI, INC. 4.56% | 1,707,473 | 4.56% | 2,527,060 $ |
CARISMA THERAPEUTICS, INC. 12.12% | 5,059,338 | 12.12% | 1,973,142 $ |
GENERATION BIO CO. 8.77% | 5,859,375 | 8.77% | 1,875,000 $ |
Company details: Moderna, Inc.
Group companies: Moderna, Inc.
| Name | Category and Sector |
|---|---|
ModernaTX, Inc.
 ModernaTX, Inc. BiotechnologyHealth Technology Modernatx, Inc. develops messenger RNA therapeutics. Its vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. The company was founded by Derrick J. Rossi, Doug G. Cole, Doug G. Cole, Robert S. Langer, Jr., Noubar Afeyan, and Kenneth R. Chien in 2011 and is headquartered in Cambridge, MA. |
Biotechnology
|
Moderna Switzerland GmbH |
Biopharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.87% | +10.33% | -72.61% | -80.81% | 13.01B | ||
| -0.61% | -0.76% | -20.24% | -16.34% | 76.69B | ||
| +1.43% | +3.72% | -47.44% | -7.60% | 59.99B | ||
| -2.13% | +5.70% | +29.69% | +27.50% | 54.72B | ||
| -0.96% | +1.21% | +18.22% | +97.45% | 37.99B | ||
| -0.83% | +1.01% | -43.32% | -37.65% | 19.67B | ||
| +0.37% | -6.55% | +110.04% | +120.99% | 17.54B | ||
| -2.23% | +16.91% | +62.89% | +752.43% | 17.06B | ||
| -0.04% | -.--% | +68.37% | +138.03% | 14.02B | ||
| -2.49% | +0.20% | +10.11% | -15.28% | 13.28B | ||
| Average | -1.14% | +1.92% | +11.57% | +97.87% | 32.4B | |
| Weighted average by Cap. | -1.19% | +1.52% | +0.68% | +56.80% |
Sector
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- MRNA Stock
- Company Moderna, Inc.
Select your edition
All financial news and data tailored to specific country editions
